Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)

NCT02280993 is registered in ClinicalTrials.gov with Marjolein Spiering as lead sponsor.

NCT NCT02280993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02280993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Lead sponsor
Marjolein Spiering
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2014
Completion date
May 31, 2020
Enrollment
72 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, refractory, relapse